Ovarian cancer, Fallopian tube cancer, Primary peritoneal cancer
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with ovarian, fallopian tube, or primary peritoneal cancer 2. Patients diagnosed with FIGO(2014) stage III or IV 3 .Patients with complete or partial response by the initial platinum-based chemotherapy 4. Patients who started Olaparib plus bevacizuma maintenance therapy after January 2021 5. Japanese female patients aged =>18 years (At the time of niraparib administration)
Exclusion criteria
Exclusion criteria: 1. Patients with active double cancer 2. Patients judged by the investigator to be inappropriate for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| -Progression-free survival (PFS) and PFS rate -Response rate in patients with residual disease (ORR) -Overall survival (OS) -Relationship to subsequent therapy, platinum-free interval -Incidence of secondary cancer | — |
Countries
Japan
Contacts
National Hospital Organization Kyoto Medical Center Department of Obstetrics and Gynecology